We use cookies for a better user experience. Read our Privacy Policy
I Agree
Dementia Associated with Alzimer’s Disease Market
The dementia associated with Alzheimer’s disease market is expected to reach a market value of about US$ 6,936.8 Mn by the end of 2026, expanding at a single digit CAGR during the forecast period. Rise in R&D expenditure, increased prevalence of Alzheimer’s across the globe, increased geriatric population, rise in awareness regarding neurodegenerative diseases in developing countries, and rich pipeline of innovative treatment options are expected to boost the dementia associated with Alzheimer’s disease market during the forecast period. Moreover, increasing research and development activities in disease modifying drugs and surge in investment by key players in the clinical studies of advanced treatment options are expected to propel the dementia associated with Alzheimer’s disease market during the forecast period. However, the high cost of advanced treatments and severe side-effects associated with certain treatments are expected to hamper the dementia associated with Alzheimer’s disease market.
The global dementia associated with Alzheimer’s disease market has been segmented based on drug class and distribution channel. In terms of drug class, the global market has been classified into cholinergic/ cholinesterase (ChE) inhibitor, memantine, and combined drug (memantine & donepezil) and others. The cholinergic/ cholinesterase (ChE) inhibitor segment dominates the dementia associated with Alzheimer’s disease market, in terms of value, as it is first line of treatment for AD and most widely prescribed drug for the treatment of AD. This segment is also expected to expand at a significant CAGR, owing to its effectiveness in the treatment of mild to severe dementia. Currently, there is no disease modifying treatment available for Alzheimer’s, and the only approved treatment for the symptomatic relief of AD are cholinesterase inhibitors (Aricept, and memantine. The memantine segment is expected to expand at a notable CAGR, owing to its ability to treat moderate to severe AD and its suitability in cholinergic/ cholinesterase (chE) inhibitors intolerant patients suffering from AD.
In terms of distribution channel, the dementia associated with Alzheimer’s disease market has been segregated into hospital pharmacies, retail, and online sales. The hospital pharmacies segment held a major share of the market in 2017, followed by retail. The hospital pharmacies segment is expected to maintain its market share during forecast period due to availability of cost-effective medications for the treatment of AD. The online pharmacies segment is projected to expand at a considerable CAGR during the forecast period, owing to easy availability of drugs at home at a discounted price and long-term treatment required for the treatment of Alzheimer’s disease.
In terms of geography, the dementia associated with Alzheimer’s disease market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the dementia associated with Alzheimer’s disease market owing to high awareness regarding Alzheimer’s disease in the U.S. and increased prevalence of AD in the region. According to the World Alzheimer’s Report, Alzheimer’s is the sixth-leading cause of death in the U.S. and currently, more than 5 million Americans are living with Alzheimer’s. Rising incidence of Alzheimer’s in elderly age group and demand for advanced therapies and disease modifying drugs is a major factor driving the market in North America. The market in Asia Pacific is projected to expand at a significantly high CAGR during the forecast period, owing to improving health care infrastructure and rising awareness regarding Alzheimer’s in countries such as China and India.
Major players operating in the dementia associated with Alzheimer’s disease market include Merz Pharma GmbH & Co. KGaA., Novartis AG, Allergan plc., Pfizer, Inc., Daiichi Sankyo Company, Limited, Ono Pharmaceutical Co., Ltd, Johnson & Johnson Services, Inc., Eisai Co., Ltd., H. Lundbeck A/S, and F. Hoffmann-La Roche Ltd. Key players are expanding their product portfolios through mergers & acquisitions and partnerships & collaborations with leading pharmaceutical and biotechnology companies and by offering technologically advanced products.
Dementia Associated with Alzheimer’s Disease Market - Snapshot
Alzheimer's is the most common cause of dementia, a general term for memory loss and other cognitive abilities serious enough to interfere with daily life. Alzheimer's disease accounts for 60-80% of dementia cases. Dementia associated with Alzheimer's disease is not a normal part of aging. The greatest known risk factor is increasing age, and the majority of people with Alzheimer's are 65 and older. But dementia associated with Alzheimer's disease is not just a disease of old age. Alzheimer's worsens over time. Alzheimer's is a progressive disease, where dementia symptoms gradually worsen over a number of years. In its early stages, memory loss is mild, but with late-stage Alzheimer's, individuals lose the ability to carry on a conversation and respond to their environment. Alzheimer's is the sixth leading cause of death in the United States. On average, a person with Alzheimer's lives four to eight years after diagnosis, but can live as long as 20 years, depending on other factors.
Dementia associated with Alzheimer's disease has no current cure, but treatments for symptoms are available and research continues. Although current Alzheimer's treatments cannot stop Alzheimer's from progressing, they can temporarily slow the worsening of dementia symptoms and improve quality of life for those with dementia associated with Alzheimer's disease and their caregivers. Today, there is a worldwide effort under way to find better ways to treat the disease, delay its onset, and prevent it from developing. The most common early symptom of Alzheimer's is difficulty remembering newly learned information.
The most common early symptom of Alzheimer's is difficulty remembering newly learned information because Alzheimer's changes typically begin in the part of the brain that affects learning. As Alzheimer's advances through the brain it leads to increasingly severe symptoms, including disorientation, mood and behavior changes. Signs of dementia associated with Alzheimer’s disease may be more obvious to family members or friends. Anyone experiencing dementia-like symptoms should see a doctor as soon as possible.
The global dementia associated with Alzheimer’s disease market has been segmented as below:
|
Drug Class |
|
|
Distribution Channel |
|
|
Region |
|
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Dementia Associated with Alzheimer's Disease Market
4. Market Overview
4.1. Introduction
4.1.1. Drug Class Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Dementia Associated with Alzheimer's Disease Market Analysis and Forecast, 2016–2026
4.4.1. Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Projections
4.5. Porter’s Five Force Analysis
5. Market Outlook
5.1. Disease Prevalence & Incidence Rate Globally with Key Countries
5.2. Pipeline Analysis
6. Global Dementia Associated with Alzheimer's disease Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Dementia Associated with Alzheimer's disease Market Value Forecast, by Drug Class, 2016–2026
6.3.1. Cholinergic/ Cholinesterase (ChE) Inhibitors
6.3.1.1. Donepezil
6.3.1.2. Galantamine
6.3.1.3. Rivastigmine
6.3.2. Memantine
6.3.3. Combined Drug (Memantine & Donepezil) and Others
6.4. Global Dementia Associated with Alzheimer's disease Market Attractiveness, by Drug Class
7. Global Dementia Associated with Alzheimer's disease Market Analysis and Forecast, by Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Dementia Associated with Alzheimer's Disease Market Value Forecast, by Distribution Channel, 2016–2026
7.3.1. Hospital Pharmacies
7.3.2. Retail
7.3.3. Online Sales
7.4. Global Dementia Associated with Alzheimer's Disease Market Attractiveness, by Distribution Channel
8. Global Dementia Associated with Alzheimer's Disease Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Global Dementia Associated with Alzheimer's Disease Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Global Dementia Associated with Alzheimer's Disease Market Attractiveness, by Country/Region
9. North America Dementia Associated with Alzheimer's Disease Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. North America Dementia Associated with Alzheimer's Disease Market Value Forecast, by Drug Class, 2016–2026
9.2.1. Cholinergic/ Cholinesterase (ChE) Inhibitors
9.2.1.1. Donepezil
9.2.1.2. Galantamine
9.2.1.3. Rivastigmine
9.2.2. Memantine
9.2.3. Combined Drug (Memantine & Donepezil) and Others
9.3. North America Dementia Associated with Alzheimer's Disease Market Value Forecast, by Distribution Channel, 2016–2026
9.3.1. Hospital Pharmacies
9.3.2. Retail
9.3.3. Online Sales
9.4. North America Dementia Associated with Alzheimer's Disease Market Value Forecast, by Country, 2016–2026
9.4.1. U.S.
9.4.2. Canada
9.5. North America Dementia Associated with Alzheimer's Disease Market Attractiveness Analysis
9.5.1. By Drug Class
9.5.2. By Distribution Channel
9.5.3. By Country
10. Europe Dementia Associated with Alzheimer's Disease Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Europe Dementia Associated with Alzheimer's Disease Market Value Forecast, by Drug Class, 2016–2026
10.2.1. Cholinergic/ Cholinesterase (ChE) Inhibitors
10.2.1.1. Donepezil
10.2.1.2. Galantamine
10.2.1.3. Rivastigmine
10.2.2. Memantine
10.2.3. Combined Drug (Memantine & Donepezil) and Others
10.3. Europe Dementia Associated with Alzheimer's Disease Market Value Forecast, by Distribution Channel, 2016–2026
10.3.1. Hospital Pharmacies
10.3.2. Retail
10.3.3. Online Sales
10.4. Europe Dementia Associated with Alzheimer's Disease Market Value Forecast, by Country/Sub-region, 2016–2026
10.4.1. Germany
10.4.2. France
10.4.3. U.K.
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Europe Dementia Associated with Alzheimer's Disease Market Attractiveness Analysis
10.5.1. By Drug Class
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region
11. Asia Pacific Dementia Associated with Alzheimer's Disease Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Asia Pacific Dementia Associated with Alzheimer's Disease Market Value Forecast, by Drug Class, 2016–2026
11.2.1. Cholinergic/ Cholinesterase (ChE) Inhibitors
11.2.1.1. Donepezil
11.2.1.2. Galantamine
11.2.1.3. Rivastigmine
11.2.2. Memantine
11.2.3. Combined Drug (Memantine & Donepezil) and Others
11.3. Asia Pacific Dementia Associated with Alzheimer's Disease Market Value Forecast, by Distribution Channel, 2016–2026
11.3.1. Hospital Pharmacies
11.3.2. Retail
11.3.3. Online Sales
11.4. Asia Pacific Dementia Associated with Alzheimer's Disease Market Value Forecast, by Country/Sub-region, 2016–2026
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Asia Pacific Dementia Associated with Alzheimer's Disease Market Attractiveness Analysis
11.5.1. By Drug Class
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region
12. Latin America Dementia Associated with Alzheimer's Disease Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Latin America Dementia Associated with Alzheimer's Disease Market Value Forecast, by Drug Class, 2016–2026
12.2.1. Cholinergic/ Cholinesterase (ChE) Inhibitors
12.2.1.1. Donepezil
12.2.1.2. Galantamine
12.2.1.3. Rivastigmine
12.2.2. Memantine
12.2.3. Combined Drug (Memantine &Donepezil) and Others
12.3. Latin America Dementia Associated with Alzheimer's Disease Market Value Forecast, by Distribution Channel, 2016–2026
12.3.1. Hospital Pharmacies
12.3.2. Retail
12.3.3. Online Sales
12.4. Latin America Dementia Associated with Alzheimer's Disease Market Value Forecast, by Country/Sub-region, 2016–2026
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America Dementia Associated with Alzheimer's Disease Market Attractiveness Analysis
12.5.1. By Drug Class
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region
13. Middle East & Africa Dementia Associated with Alzheimer's Disease Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Middle East & Africa Dementia Associated with Alzheimer's Disease Market Value Forecast, by Drug Class, 2016–2026
13.2.1. Cholinergic/ Cholinesterase (ChE) Inhibitors
13.2.1.1. Donepezil
13.2.1.2. Galantamine
13.2.1.3. Rivastigmine
13.2.2. Memantine
13.2.3. Combined Drug (Memantine & Donepezil) and Others
13.3. Middle East & Africa Dementia Associated with Alzheimer's Disease Market Value Forecast, by Distribution Channel, 2016–2026
13.3.1. Hospital Pharmacies
13.3.2. Retail
13.3.3. Online Sales
13.4. Middle East & Africa Dementia Associated with Alzheimer's Disease Market Value Forecast, by Country/Sub-region, 2016–2026
13.4.1. GCC Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. Middle East & Africa Dementia Associated with Alzheimer's Disease Market Attractiveness Analysis
13.5.1. By Drug Class
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of companies)
14.2. Market Share Analysis by Company (2016)
14.3. Market Footprint Analysis
14.3.1. By Region
14.3.2. By Drug Class Type
14.4. Competitive Business Strategies
14.5. Company Profiles
14.5.1. Merz Pharma GmbH & Co. KGaA
14.5.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.1.2. Product Portfolio
14.5.1.3. SWOT Analysis
14.5.1.4. Financial Overview
14.5.1.5. Strategic Overview
14.5.2. Novartis AG
14.5.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.2.2. Product Portfolio
14.5.2.3. SWOT Analysis
14.5.2.4. Financial Overview
14.5.2.5. Strategic Overview
14.5.3. Allergan plc.
14.5.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.3.2. Product Portfolio
14.5.3.3. SWOT Analysis
14.5.3.4. Financial Overview
14.5.3.5. Strategic Overview
14.5.4. Pfizer, Inc.
14.5.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.4.2. Product Portfolio
14.5.4.3. SWOT Analysis
14.5.4.4. Financial Overview
14.5.4.5. Strategic Overview
14.5.5. Daiichi Sankyo Company, Limited
14.5.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.5.2. Product Portfolio
14.5.5.3. SWOT Analysis
14.5.5.4. Financial Overview
14.5.5.5. Strategic Overview
14.5.6. Ono Pharmaceutical Co., Ltd.
14.5.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.6.2. Product Portfolio
14.5.6.3. SWOT Analysis
14.5.6.4. Financial Overview
14.5.6.5. Strategic Overview
14.5.7. Johnson & Johnson Services, Inc.
14.5.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.7.2. Product Portfolio
14.5.7.3. SWOT Analysis
14.5.7.4. Financial Overview
14.5.7.5. Strategic Overview
14.5.8. Eisai Co., Ltd.
14.5.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.8.2. Product Portfolio
14.5.8.3. SWOT Analysis
14.5.8.4. Financial Overview
14.5.8.5. Strategic Overview
14.5.9. H. Lundbeck A/S
14.5.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.9.2. Product Portfolio
14.5.9.3. SWOT Analysis
14.5.9.4. Financial Overview
14.5.9.5. Strategic Overview
14.5.10. F. Hoffmann-La Roche Ltd.
14.5.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.10.2. Product Portfolio
14.5.10.3. SWOT Analysis
14.5.10.4. Financial Overview
14.5.10.5. Strategic Overvie
List of Tables
Table 01: Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 02: Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast, by Cholinergic/ Cholinesterase (ChE) Inhibitors, 2016–2026
Table 03: Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 04: Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast, by Region, 2016–2026
Table 05: North America Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast, by Country, 2016–2026
Table 06: North America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 07: North America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, (Cholinergic/ Cholinesterase (ChE) Inhibitors), 2016–2026
Table 08: North America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 09: Europe Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 10: Europe Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 11: Europe Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, (Cholinergic/ Cholinesterase (ChE) Inhibitors), 2016–2026
Table 12: Europe Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 13: Asia Pacific Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 14: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 15: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, (Cholinergic/ Cholinesterase (ChE) Inhibitors), 2016–2026
Table 16: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 17: Latin America Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 18: Latin America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 19: Latin America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, (Cholinergic/ Cholinesterase (ChE) Inhibitors), 2016–2026
Table 20: Latin America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 21: Middle East & Africa Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 22: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 23: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, (Cholinergic/ Cholinesterase (ChE) Inhibitors), 2016–2026
Table 24: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–202
List of Figures
Figure 01: Dementia Associated with Alzheimer's Disease Market Size (US$ Mn) and Distribution, by Region, 2018 and 2026
Figure 02: Dementia Associated with Alzheimer's Disease Market Value Forecast, by Drug Class, 2018(E)
Figure 03: Dementia Associated with Alzheimer's Disease Market Snapshot
Figure 04: Dementia Associated with Alzheimer's Disease Market Value Share
Figure 05: Dementia Associated with Alzheimer's Disease Market Value Share
Figure 06: Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast, 2016–2026
Figure 07: Global Dementia Associated with Alzheimer's Disease Market Value Share, by Drug Class, 2017
Figure 08: Global Dementia Associated with Alzheimer's Disease Market Value Share, by Distribution Channel, 2017
Figure 09: Global Dementia Associated with Alzheimer's Disease Market Value Share, by Region, 2017
Figure 10: Global Dementia Associated with Alzheimer's Disease Market Value Share Analysis, by Drug Class, 2018 and 2026
Figure 11: Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Cholinergic/ Cholinesterase (ChE)Inhibitor
Figure 12: Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Memantine
Figure 13: Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Combined Drug (Memantine & Donepezil) and Others
Figure 14: Global Dementia Associated with Alzheimer's Disease Market Attractiveness Analysis, by Drug Class, 2018–2026
Figure 15: Global Dementia Associated with Alzheimer's Disease Market Value Share Analysis, by Distribution Channel, 2018 and 2026
Figure 16: Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies
Figure 17: Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Retail
Figure 18: Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Online Sales
Figure 19: Global Dementia Associated with Alzheimer's Disease Market Attractiveness Analysis, by Distribution Channel
Figure 20: Global Dementia Associated with Alzheimer's Disease Market Value Share, by Region, 2018 and 2026
Figure 21: Global Dementia Associated with Alzheimer's Disease Market Attractiveness Analysis, by Region, 2018–2026
Figure 22: North America Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
Figure 23: North America Dementia Associated with Alzheimer's Disease Market Value Share, by Country, 2017 and 2026
Figure 24: North America Dementia Associated with Alzheimer's Disease Market Attractiveness, by Country, 2018–2026
Figure 25: North America Dementia Associated with Alzheimer's Disease Market Value Share, by Drug Class, 2017 and 2026
Figure 26: North America Dementia Associated with Alzheimer's Disease Market Attractiveness, by Drug Class, 2018–2026
Figure 27: North America Dementia Associated with Alzheimer's Disease Market Value Share, by Animal Type, 2017 and 2026
Figure 28: North America Dementia Associated with Alzheimer's Disease Market Attractiveness, by Animal Type, 2018–2026
Figure 29: Europe Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
Figure 30: Europe Dementia Associated with Alzheimer's Disease Market Value Share, by Country/Sub-region, 2017 and 2026
Figure 31: Europe Dementia Associated with Alzheimer's Disease Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 32: Europe Dementia Associated with Alzheimer's Disease Market Value Share, by Drug Class, 2017 and 2026
Figure 33: Europe Dementia Associated with Alzheimer's Disease Market Attractiveness, by Drug Class, 2018–2026
Figure 34: Europe Dementia Associated with Alzheimer's Disease Market Value Share, by Distribution Channel, 2017 and 2026
Figure 35: Europe Dementia Associated with Alzheimer's Disease Market Attractiveness, by Distribution Channel, 2018–2026
Figure 36: Asia Pacific Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
Figure 37: Asia Pacific Dementia Associated with Alzheimer's Disease Market Value Share, by Country/Sub-region, 2017 and 2026
Figure 38: Asia Pacific Dementia Associated with Alzheimer's Disease Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 39: Asia Pacific Dementia Associated with Alzheimer's Disease Market Value Share, by Drug Class, 2017 and 2026
Figure 40: Asia Pacific Dementia Associated with Alzheimer's Disease Market Attractiveness, by Drug Class, 2018–2026
Figure 41: Asia Pacific Dementia Associated with Alzheimer's Disease Market Value Share, by Distribution Channel, 2017 and 2026
Figure 42: Asia Pacific Dementia Associated with Alzheimer's Disease Market Attractiveness, by Distribution Channel, 2018–2026
Figure 43: Latin America Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
Figure 44: Latin America Dementia Associated with Alzheimer's Disease Market Value Share, by Country/Sub-region, 2017 and 2026
Figure 45: Latin America Dementia Associated with Alzheimer's Disease Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 46: Latin America Dementia Associated with Alzheimer's Disease Market Value Share, by Drug Class, 2017 and 2026
Figure 47: Latin America Dementia Associated with Alzheimer's Disease Market Attractiveness, by Drug Class, 2018–2026
Figure 48: Latin America Dementia Associated with Alzheimer's Disease Market Value Share, by Animal Type, 2017 and 2026
Figure 49: Latin America Dementia Associated with Alzheimer's Disease Market Attractiveness, by Animal Type, 2018–2026
Figure 50: Middle East & Africa Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
Figure 51: Middle East & Africa Dementia Associated with Alzheimer's Disease Market Value Share, by Country/Sub-region, 2017 and 2026
Figure 52: Middle East & Africa Dementia Associated with Alzheimer's Disease Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 53: Middle East & Africa Dementia Associated with Alzheimer's Disease Market Value Share, by Drug Class, 2017 and 2026
Figure 54: Middle East & Africa Dementia Associated with Alzheimer's Disease Market Attractiveness, by Drug Class, 2018–2026
Figure 55: Middle East & Africa Dementia Associated with Alzheimer's Disease Market Value Share, by Distribution Channel, 2017 and 2026
Figure 56: Middle East & Africa Dementia Associated with Alzheimer's Disease Market Attractiveness, by Distribution Channel, 2018–2026
Figure 57: Merz Pharma GmbH & Co. KGaA Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 58: Merz Pharma GmbH & Co. KGaA R&D Expenses, 2016–2017
Figure 59: Merz Pharma GmbH & Co. KGaA Breakdown of Net Sales, by Region, 2017
Figure 60: Merz Pharma GmbH & Co. KGaA Breakdown of Net Sales, by Business Segment, 2017
Figure 61: Novartis AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 62: Novartis AG R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 63: Novartis AG Breakdown of Net Sales, by Region, 2017
Figure 64: Novartis AG Breakdown of Net Sales, by Business Segment, 2017
Figure 65: Allergan plc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2017
Figure 66: Allergen plc. R&D Expenses, 2016–2017
Figure 67: Allergan plc. Sales and Marketing Expenses, 2017
Figure 68: Allergan plc. Breakdown of Net Sales, by Business Segment, 2017
Figure 69: Pfizer, Inc. Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2017
Figure 70: Pfizer, Inc. R&D Expenses and SI&A Expenses (%) 2015–2017
Figure 71: Pfizer, Inc. Breakdown of Net Sales, by Geography (Essential Health Segment), 2017
Figure 72: Pfizer, Inc. Breakdown of Net Sales, by Product (%), 2017
Figure 73: Daiichi Sankyo Company, Limited Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2017
Figure 74: Daiichi Sankyo Company, Limited R&D Expenses (US$ Bn), 2016–2017
Figure 75: Daiichi Sankyo Company, Limited Breakdown of Net Sales, by Region, 2017
Figure 76: Ono Pharmaceutical Co., Ltd. Research & Development Expenses (US$ Mn) and Y-o-Y Growth (%), 2015-2017
Figure 77: Ono Pharmaceutical Co., Ltd. Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2017
Figure 78: Ono Pharmaceutical Co., Ltd. Breakdown of Net Sales, by Geography, 2017
Figure 79: Johnson & Johnson Services, Inc. Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
Figure 80: Johnson & Johnson Services, Inc. Pharmaceutical Products Segment Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
Figure 81: Johnson & Johnson Services, Inc. Breakdown of Net Sales, by Business Segment, 2017
Figure 82: Johnson & Johnson Services, Inc. Research & Development Cost, 2015 – 2017 (US$ Bn)
Figure 83: Eisai Co., Ltd. Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2017
Figure 84: Eisai Co., Ltd. Breakdown of Net Sales, by Business
Figure 85: H. Lundbeck A/S Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
Figure 86: H. Lundbeck A/S Breakdown of Net Sales, by Region, 2017
Figure 87: H. Lundbeck A/S Research & Development Cost, 2015 – 2017 (US$ Mn)
Figure 88: F. Hoffmann-La Roche Ltd. Breakdown of Net Sales, by Business Segment, 2017
Figure 89: F. Hoffmann-La Roche Ltd. Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
Figure 90: F. Hoffmann-La Roche Ltd. Research & Development Cost, 2015 – 2017 (US$ Bn
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
*86 figures and 60 tables includes